CoChat

ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation: Joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine

Open access

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Abstract

The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medical services using these devices. In the absence of suitable commercial devices, the laboratory can resort to laboratory-developed tests (LDT) for in-house use. Documentary obligations (IVDR Art 5.5), the performance and safety specifications of ANNEX I, and development and manufacture under an ISO 15189-equivalent quality system apply. LDTs serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments, often extremely relevant for patient care. As some commercial tests may disappear with the IVDR roll-out, many will require urgent LDT replacement. The workload will also depend on which modifications to commercial tests turns them into an LDT, and on how national legislators and competent authorities (CA) will handle new competences and responsibilities. We discuss appropriate interpretation of ISO 15189 to cover IVDR requirements. Selected cases illustrate LDT implementation covering medical needs with commensurate management of risk emanating from intended use and/or design of devices. Unintended collateral damage of the IVDR comprises loss of non-profitable niche applications, increases of costs and wasted resources, and migration of innovative research to more cost-efficient environments. Taking into account local specifics, the legislative framework should reduce the burden on and associated opportunity costs for the health care system, by making diligent use of existing frameworks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1515/cclm-2023-0045

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 11

  1. European Parliament and Council Regulation (EU) 2017/745 of 5 April 2017 on medical devices: Official Journal of the European Union; 2017, vol 117:1–175 pp. Available from: http://data.europa.eu/eli/reg/2017/745/oj [Accessed 3 Jun 2022].
  2. European Parliament and Council Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices: Official Journal of the European Union; 2017, vol 117:176–332 pp. Available from: http://data.europa.eu/eli/reg/2017/746/oj [Accessed 5 Jul 2022].
  3. European Parliament and Council Regulation (EU) 2022/112 of 25 January 2022 amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices: Official Journal of the European Union
  4. European Commission Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 (Text with EEA relevance): Official Journal of the European Union
  5. Patra, KP, De Jesus, O. Sentinel event: StatPearls Publishing; 2021. PMID: 33232058. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564388/[Accessed 11 Jun 2022].
  6. Janssens, PMW. Lessen uit en over de analyse van bijzondere vochten. Ned Tijdschr Klin Chem Lab 2017;42:2–15.
  7. European Parliament and Council Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance: Official Journal of the European Union
  8. European Parliament and Council. Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation): Official Journal of the European Union
  9. 2016, 119:1-88 pp. Available from: http://data.europa.eu/eli/reg/2016/679/oj [Accessed 4 Dec 2022].
  10. European Parliament and Council Directive 2014/24/EU of 26 February 2014 on public procurement and repealing Directive 2004/18/EC: Official Journal of the European Union
  11. European Council, Council regulation (EC) No 1/2003 of 16 December 2002 on the implementation of the rules on competition laid down in Articles 81 and 82 of the Treaty: Official Journal of the European Union

Cited by

See all 45

Metadata

Authors
Vanstapel, F. J. L. A., Orth, M., Streichert, T., Capoluongo, E. D., Oosterhuis, W. P., Çubukçu, H. C., Bernabeu-Andreu, F. A., Thelen, M., Jacobs, L. H. J., Linko, S., Bhattoa, H. P., Bossuyt, P. M. M., Meško Brguljan, P., Boursier, G., Cobbaert, C. M., & Neumaier, M.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Heidelberg University (DE)
  • University of Cologne (DE)
  • University of Naples Federico II (IT)
  • Department of Clinical Chemistry , Reinier Haga Medical Diagnostic Centre , Delft , The Netherlands
  • Ministry of Health (TR)
  • Servicio Bioquímica Análisis Clínicos ,  Hospital Universitario Puerta de Hierro Majadahonda (Madrid) , Majadahonda , Spain
  • Radboud University Medical Center (NL)
  • Meander Medisch Centrum (NL)
  • Linko Q-Solutions , Helsinki , Finland
  • University of Debrecen (HU)
  • Amsterdam University Medical Centers (NL)
  • Department of Clinical Chemistry , University Clinic for Respiratory and Allergic Diseases Golnik , Golnik , Slovenia
  • Université de Montpellier (FR)
  • Leiden University Medical Center (NL)
Corresponding author
Vanstapel, Florent J.L.A.
Venue
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2023-01-31
Volume
61
Issue
4
Pages
608-626
ISSN
  • 1434-6621 (ISSN-L)
  • 1437-4331
OpenAlex
W4318542353
Cited by
45
References
42
Citations by year
2026: 9 · 2025: 15 · 2024: 12 · 2023: 9
FWCI
1.59
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, public-domain)
  • Lirias (submittedVersion, public-domain)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
ISO 15189, laboratory-developed tests, IVDR, in vitro diagnostic regulation, quality management systems, post-marketing surveillance, regulatory burden
MeSH terms
European Union, Humans, Reagent Kits, Diagnostic, Clinical Laboratory Services

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation: Joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine. https://app.cochat.ai/papers/10.1515/cclm-2023-0045
The paper
Vanstapel, F. J. L. A., Orth, M., Streichert, T., Capoluongo, E. D., Oosterhuis, W. P., Çubukçu, H. C., Bernabeu-Andreu, F. A., Thelen, M., Jacobs, L. H. J., Linko, S., Bhattoa, H. P., Bossuyt, P. M. M., Meško Brguljan, P., Boursier, G., Cobbaert, C. M., & Neumaier, M. (2023). ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation: Joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2023-0045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.